Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis
Neurological Sciences · 2025
DOI: 10.1007/s10072-025-08196-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2025. Verfasst von Hee Jo Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
BACKGROUND: The long lead time required to diagnose refractory myasthenia gravis (MG) can prevent early attempts at new treatments. Herein, we aimed to predict refractory MG by comparing treatment responses during the early stages between patients with refractory and non-refractory MG. METHODS: We retrospectively investigated the medical records of patients with acetylcholine receptor antibody-positive generalized MG. Refractory MG was defined as (1) inability to lower prednisolone below 20 mg/day, (2) requiring regular intravenous immunoglobulin or plasmapheresis, or (3) Myasthenia Gravis Activities of Daily Living score ≥ 6 after treatment with corticosteroids and ≥ 1 oral immunosuppressant for ≥ 12 months. RESULTS: Of 133 patients, 29 (21.8%) and 104 (78.2%) had refractory and non-refractory MG, respectively. The median duration from the diagnosis of MG to that of refractory MG was 31 months. During the first year following diagnosis, the proportion of patients who achieved a lowest effective prednisolone dose of ≤ 20 mg was lower in the refractory group than in the non-refractory group (69.0% vs. 92.0%). Conversely, the proportions of patients who initiated oral immunosuppressive therapy (58.6% vs. 22.5%), required rescue interventions (48.3% vs. 22.1%), or experienced a myasthenic crisis (34.5% vs. 14.4%) were significantly higher in the refractory group. The risk of refractory MG was 18.7-fold higher in patients who failed to achieve lowest effective prednisolone dose under 20 mg/day and started oral immunosuppressant during the first year than those with neither of these conditions. CONCLUSIONS: The refractory group displayed distinct clinical features during the early disease stages, including frequent crises and higher levels of immunosuppressive treatment. These features can be used for early prediction of refractory MG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. kswneuro@yuhs.ac.
Förderung
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Han, H. J., Kim, S., Park, H. J., Shin, H. Y., & Kim, S. W. (2025). Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis. Neurological Sciences. https://doi.org/10.1007/s10072-025-08196-6
Vancouver
Han HJ, Kim S, Park HJ, Shin HY, Kim SW. Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis. Neurological Sciences. 2025. doi:10.1007/s10072-025-08196-6
BibTeX
@article{Han2025,
author = {Han, Hee Jo and Kim, Susung and Park, Hyung Jun and Shin, Ha Young and Kim, Seung Woo},
title = {Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-025-08196-6}
}
EUVIMED